缺失G蛋白的减毒活RSV疫苗首次人体试验:安全性、耐受性、排毒与免疫原性
该随机对照试验在RSV中和抗体滴度低于9.6 log2的健康成人中评估鼻内接种单剂6.5 log10 CCID50 RSVΔG疫苗的安全性、排毒与免疫应答。疫苗耐受良好,鼻洗液未检出感染性病毒,但血清阳性成人中和抗体应答有限,提示需在儿童及血清阴性婴儿中进一步探索。
要点
- 鼻内单剂6.5 log10 CCID50 RSVΔG在血清阳性健康成人中安全且耐受良好。
- 鼻洗液样本中未检出感染性病毒,提示疫苗减毒充分。
- 血清阳性成人接种后中和抗体应答有限,未见抗体诱导迹象。
核心结论
- 单剂6.5 log10 CCID50 RSVΔG在血清阳性健康成人中安全且耐受良好,减毒充分但未见抗体诱导迹象。
研究设计与样本
- 首次人体随机对照试验,健康成人18至50岁、RSV中和血清滴度低于9.6 log2,按3:1随机接受单剂疫苗或安慰剂,共48人。
- 评估安全性、耐受性、鼻病毒载量及全身与体液免疫应答,随访至免疫后4周。
主要发现
- 鼻内接种RSVΔG耐受良好,未发现临床关注的不良事件。
- 鼻洗液样本中未检出感染性病毒。
- 与其他减毒活RSV疫苗类似,血清阳性成人接种后中和抗体应答有限。
关键数值与推荐
- 疫苗剂量为6.5 log10 CCID50,鼻内单剂给药。
- 入组要求RSV中和血清滴度低于9.6 log2。
- 随机分组比例为疫苗组与安慰剂组3:1,总样本量48人。
临床怎么用
- 提示RSVΔG在血清阳性成人中安全性良好,但免疫原性有限,后续需在儿童及血清阴性婴儿中评估安全性与免疫原性。
局限性
- 仅纳入血清阳性健康成人,随访至免疫后4周,未评估儿童或血清阴性婴儿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in early infancy and in elderly. A pediatric vaccine against RSV would not only prevent morbidity and mortality amongst infants and young children but could also reduce transmission to elderly. The RSVΔG vaccine consists of a live-attenuated RSV that lacks the G attachment protein. RSVΔG is severely impaired in binding to host cells and exhibits reduced infectivity in preclinical studies. Intranasal immunization of cotton rats with RSVΔG vaccine protected against replication of wildtype RSV, without inducing enhanced disease. METHODS: We performed a first-in-human trial with primary objective to evaluate safety and shedding of RSVΔG (6.5 log10 CCID50) after intranasal administration. Healthy adults aged between 18 and 50, with RSV neutralizing serum titers below 9.6 log2, received a single dose of either vaccine or placebo (n = 48, ratio 3:1). In addition to safety and tolerability, nasal viral load, and systemic and humoral immune responses were assessed at selected time points until 4 weeks after immunization. RESULTS: Intranasal administration of RSVΔG was well tolerated with no findings of clinical concern. No infectious virus was detected in nasal wash samples. Similar to other live-attenuated RSV vaccines, neutralizing antibody response following inoculation was limited in seropositive adults. CONCLUSIONS: A single dose of 6.5 log10 CCID50 of RSVΔG was safe and well-tolerated in seropositive healthy adults. RSVΔG was sufficiently attenuated but there were no signs of induction of antibodies. Safety and immunogenicity can now be explored in children and eventually in seronegative infants. Clinical trial register: NTR7173/EudraCT number 2016-002437-30.
引用
- Verdijk P, van der Plas JL, van Brummelen EMJ, et al. First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial. Vaccine. 2020. PMID: 32718816. doi:10.1016/j.vaccine.2020.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。